Predictors of buprenorphine-naloxone dosing in a 12-week treatment trial for opioid-dependent youth: secondary analyses from a NIDA Clinical Trials Network study.
Predictors of buprenorphine-naloxone dosing in a 12-week treatment trial for opioid-dependent youth: secondary analyses from a NIDA Clinical Trials Network study.
复制标题
DOI：
10.1016/j.drugalcdep.2009.10.014
复制
发表时间：
2010-03-01
影响因子：
4.2
通讯作者：
Weiss RD
中科院分区：
文献类型：
--
作者：
Chakrabarti A;Woody GE;Griffin ML;Subramaniam G;Weiss RD
目前的研究检查了基线患者特征，以预测丁丙诺啡-纳洛酮的剂量，丁丙诺啡-纳洛酮是一种有希望的治疗阿片类药物成瘾的年轻人。这项对69名阿片类药物依赖青少年的研究是对国家药物滥用研究所（NIDA）临床试验网络研究期间收集的数据的二次分析。年龄15-21岁的门诊患者随机分为12周丁丙诺啡-纳洛酮给药组（包括4周逐渐减少给药）。剂量的预测因素包括社会人口学特征（性别、种族、年龄和教育程度）、物质使用（酒精、大麻、可卡因和尼古丁使用）和临床特征（疼痛和戒断严重程度）。大多数（75.4%）报告在入学时有“一些”（n=40, 58.0%）或“极端”（n=12, 17.4%）疼痛。基线时报告“极度”疼痛的患者接受的丁丙诺啡-纳洛酮的最大日剂量（19.7 mg）显著高于报告“部分”疼痛的患者（15.0 mg）和无疼痛的患者（12.8 mg）。在调整分析中，只有疼痛严重程度和戒断反应与剂量有显著关系。在给药期间，通过尿液分析和疼痛程度测量，阿片类药物的使用没有显着差异。这些数据表明，在阿片类药物依赖的青少年中，疼痛的存在预示着丁丙诺啡-纳洛酮的剂量水平，并且疼痛患者与无疼痛患者的阿片类药物使用结果相当，但需要更高的丁丙诺啡-纳洛酮剂量。
The present investigation examines baseline patient characteristics to predict dosing of buprenorphine-naloxone, a promising treatment for opioid addiction in youths. This study of 69 opioid-dependent youths is a secondary analysis of data collected during a National Institute on Drug Abuse (NIDA) Clinical Trials Network study. Outpatients aged 15-21 were randomized to a 12-week buprenorphine-naloxone dosing condition (including 4 weeks of taper). Predictors of dosing included sociodemographic characteristics (gender, race, age, and education), substance use (alcohol, cannabis, cocaine, and nicotine use), and clinical characteristics (pain and withdrawal severity). Most (75.4%) reported having either “some” (n=40, 58.0 %) or “extreme” (n=12, 17.4%) pain on enrollment. Maximum daily dose of buprenorphine-naloxone (19.7 mg) received by patients reporting “extreme” pain at baseline was significantly higher than the dose received by patients reporting “some” pain (15.0 mg) and those without pain (12.8 mg). In the adjusted analysis, only severity of pain and withdrawal significantly predicted dose. During the dosing period, there were no significant differences in opioid use, as measured by urinalysis, by level of pain. These data suggest that the presence of pain predicts buprenorphine-naloxone dose levels in opioid-dependent youth, and that patients with pain have comparable opioid use outcomes to those without pain, but require higher buprenorphine-naloxone doses.
登录
查看更多内容
影响因子：
3.4
作者：
Comer, SD;Walker, EA;Collins, ED
通讯作者：
Collins, ED
影响因子：
3.9
作者：
Gossop, M;Stewart, D;Marsden, J
通讯作者：
Marsden, J
影响因子：
2.3
作者：
Galanter, M;Dermatis, H;Neumann, E
通讯作者：
Neumann, E
影响因子：
1.9
作者：
Schottenfeld, RS;Pakes, JR;Kosten, TR
通讯作者：
Kosten, TR
影响因子：
3.9
作者：
Stein, MD;Anderson, BJ
通讯作者：
Anderson, BJ